Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Revolutionizing Healthcare by Tracking and Understanding Human Cells during Disease

Project description

Advancing the European approach to medicine

The underlying mechanisms of many complex diseases, such as cancer and neurodegenerative diseases, have not been fully elucidated. Therefore, there is a need for integrated research into chronic, incurable diseases. The EU-funded LifeTime initiative will establish a network for developing, integrating and applying several disruptive technologies to advance our understanding of disease. The consortium will comprise more than 100 research institutions who will work on single-cell analysis, advanced imaging, organoid models of disease and artificial intelligence. Collectively, their work and innovations on our genome's activity in individual cells as they progress through time (ageing or disease) are expected to redefine diagnosis and pathology. They will also advance biomedical and clinical practice, directly benefiting European patients.

Objective

"Understanding how genomes function within cells, and how cells form tissues and dynamically remodel their activities when tissues progress towards disease is among the grand science and technology challenges of our era. The early detection and interception of chronic and progressive diseases would alleviate enormous suffering and a heavy, growing burden on our economy and ageing society. LifeTime aims to revolutionize healthcare by developing and integrating several emerging, disruptive technologies (single-cell multi-omics, advanced imaging, machine learning/artificial intelligence (AI), organoids, and CRISPR-Cas). LifeTime technologies will track and decipher the activity of our genomes (our ""book of life"") in individual cells as they progress through time (ageing or disease)-""LifeTime"". LifeTime's unifying goal is to quantify, model, and predict cell trajectories in tissues and whole organisms. Its long-term vision is that LifeTime technologies will inform the physician about the molecular history of a patient's tissues, their future, and the consequences of perturbations or medical treatments, leading to early diagnosis and effective interception of disease. LifeTime scientists are world-leaders in the required technologies and are committed to establishing an open and dynamic network. LifeTime's focus on developing, integrating and applying several disruptive technologies will induce long-lasting structural changes in European life sciences and healthcare and establish leadership in AI applications for medicine. Together with many industrial partners, we will develop technologies to redefine diagnosis and pathology, and set new standards for mechanism-based drug discovery and disease management for the 21st century. Such advances and their ensuing medical transformation will significantly impact the health of European citizens and stimulate the economy with tremendous benefit for society as a whole."

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

CSA - Coordination and support action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-FETFLAG-2018-2020

See all projects funded under this call

Coordinator

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Net EU contribution
€ 596 250,00
Address
ROBERT ROSSLE STRASSE 10
13125 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
€ 621 250,00

Participants (19)